Shenzhen - Delayed Quote CNY

Fujian Wanchen Biotechnology Group Co., Ltd. (300972.SZ)

153.01
+2.98
+(1.99%)
At close: May 9 at 3:04:13 PM GMT+8
Loading Chart for 300972.SZ
  • Previous Close 150.03
  • Open 146.79
  • Bid 153.01 x --
  • Ask 153.05 x --
  • Day's Range 146.00 - 153.90
  • 52 Week Range 17.69 - 171.00
  • Volume 2,849,200
  • Avg. Volume 3,008,079
  • Market Cap (intraday) 27.54B
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) 58.85
  • EPS (TTM) 2.60
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (0.13%)
  • Ex-Dividend Date Jan 21, 2025
  • 1y Target Est 151.11

Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.

www.vanchen.com

7,904

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300972.SZ

View More

Performance Overview: 300972.SZ

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300972.SZ
90.71%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

300972.SZ
441.49%
SSE Composite Index (000001.SS)
5.95%

3-Year Return

300972.SZ
1,057.03%
SSE Composite Index (000001.SS)
11.25%

5-Year Return

300972.SZ
429.81%
SSE Composite Index (000001.SS)
15.43%

Compare To: 300972.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300972.SZ

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    27.00B

  • Enterprise Value

    25.80B

  • Trailing P/E

    57.64

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.76

  • Price/Book (mrq)

    20.40

  • Enterprise Value/Revenue

    0.67

  • Enterprise Value/EBITDA

    17.21

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.31%

  • Return on Assets (ttm)

    15.43%

  • Return on Equity (ttm)

    64.79%

  • Revenue (ttm)

    38.32B

  • Net Income Avi to Common (ttm)

    502.14M

  • Diluted EPS (ttm)

    2.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3B

  • Total Debt/Equity (mrq)

    97.05%

  • Levered Free Cash Flow (ttm)

    1.06B

Research Analysis: 300972.SZ

View More

Company Insights: 300972.SZ

Research Reports: 300972.SZ

View More

People Also Watch